Renin test-guided drug treatment of hypertension: The need for clinical trials

American Journal of Hypertension

Volumn 24, Issue 11, 2011, Pages 1158-1163

  Furberg, Curt D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; RENIN; SODIUM;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); CUSHING SYNDROME; ESSENTIAL HYPERTENSION; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY FAILURE; MONOTHERAPY; NOTE; PATHOPHYSIOLOGY; PATIENT CARE; PHEOCHROMOCYTOMA; PLASMA RENIN ACTIVITY; PRACTICE GUIDELINE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RANDOMIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASOCONSTRICTION;

ANGIOTENSINS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; EXTRACELLULAR FLUID; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM;

EID: 80054889587     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.170     Document Type: Note

References (20)

1. Furberg CD. Renin-guided treatment of hypertension: time for action. Am J Hypertens 2010; 23:929-930.
2. Drayer JI, Keim HJ, Weber MA, Case DB, Laragh JH. Unexpected pressor responses to propranolol in essential hypertension. An interaction between renin, aldosterone and sympathetic activity. Am J Med 1976; 60:897-903.
3. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009; 22:112-121.
4. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens 2010; 23:1031-1037.
5. Sim JJ, Bhandari SK, Shi J, Kalantar-Zadeh K, Rasgon SA, Sealey JE. Use of antihypertensive medications in a large healthcare system: relationship to plasma renin activity (PRA) levels. Am J Hypertens, in press.
6. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to longterm blood pressure. Am J Hypertens 2011; 24:1164-1180.
7. Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH 3rd, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009; 22:792-801.
8. Bühler FR, Laragh JH, Baer L, Vaughan ED Jr, Brunner HR. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renindependent hypertensive diseases. N Engl J Med 1972; 287:1209-1214.
9. Bühler FR, Laragh JH, Vaughan ED Jr, Brunner HR, Gavras H, Baer L. Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 1973; 32:511-522.
10. Vaughan ED Jr, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol 1973; 32:523-532.
11. Weber MA, Drayer JI, Rev A, Laragh JH. Disparate patterns of aldosterone response during diuretic treatment of hypertension. Ann Intern Med 1977; 87:558-563. (Pubitemid 8223602)
12. Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11:894-896. (Pubitemid 28351031)
13. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010; 23:1014-1022.
14. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52:633-652.
15. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973; 55: 261-274.
16. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14:491-503. (Pubitemid 32506721)
17. Sealey JE, Parra D, Rosenstein R, Laragh JH. "Effective" plasma renin activity: a derived measure for assessing residual plasma renin activity in patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Hypertension 2010; 55:e16; author reply e17.
18. Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MH. Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens 2011; 24:1181-1186.
19. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
20. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043-2050.